Immunosuppression and outcomes of patients transplanted for hepatitis C
Open Access
- 30 April 2006
- journal article
- editorial
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (4) , 627-629
- https://doi.org/10.1016/j.jhep.2006.02.002
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized studyJournal of Hepatology, 2006
- Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrenceJournal of Hepatology, 2006
- Addition of MMF to Dual Immunosuppression Does Not Increase the Risk of Malignant Short‐Term Death After Liver TransplantationAmerican Journal of Transplantation, 2005
- Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-upTransplantation, 2004
- The role of immunosuppression in recurrence of hepatitis CLiver Transplantation, 2003
- Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1Transplantation, 2003
- A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis CLiver Transplantation, 2002
- Defining the outcome of immunosuppression withdrawal after liver transplantationHepatology, 1998
- Diabetes mellitus after liver transplantation: prevalence and predictive factorsJournal of Hepatology, 1996
- Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantationHepatology, 1995